Efficacy and safety of ertugliflozin in type 2 diabetes monotherapy in the extension of the VERTIS MONO study. Comment
2020
Abstract
Ertugliflozin is another member of the group of SGLT inhibitors - antidiabetics that improve glycemic control without the risk of hypoglycemia.